Presentation is loading. Please wait.

Presentation is loading. Please wait.

Abdominal adipose tissue depots and pancreatic volume in a 29-year-old non-obese (BMI: 21.9 kg/m2) patient with type 2 diabetes, images obtained using.

Published byสาวิทย์ วอชิงตัน Modified over 5 years ago

Similar presentations

Presentation on theme: "Abdominal adipose tissue depots and pancreatic volume in a 29-year-old non-obese (BMI: 21.9 kg/m2) patient with type 2 diabetes, images obtained using."— Presentation transcript:

1 Abdominal adipose tissue depots and pancreatic volume in a 29-year-old non-obese (BMI: 21.9 kg/m2) patient with type 2 diabetes, images obtained using MRI (1.5 Tesla) and quantified by ROI analysis using GE Advantage Workstation Volume Viewer softwares. Abdominal adipose tissue depots and pancreatic volume in a 29-year-old non-obese (BMI: 21.9 kg/m2) patient with type 2 diabetes, images obtained using MRI (1.5 Tesla) and quantified by ROI analysis using GE Advantage Workstation Volume Viewer softwares. (A) Superficial subcutaneous abdominal adipose tissue, (B) Deep subcutaneous abdominal adipose tissue, (C) Anterior subcutaneous abdominal adipose tissue, (D) Posterior subcutaneous abdominal adipose tissue, (E) Intraperitoneal adipose tissue and (F) Retroperitoneal adipose tissue. Shajith Anoop et al. BMJ Open Diab Res Care 2017;5:bmjdrc ©2017 by American Diabetes Association

Download ppt "Abdominal adipose tissue depots and pancreatic volume in a 29-year-old non-obese (BMI: 21.9 kg/m2) patient with type 2 diabetes, images obtained using."

Similar presentations

Imaging studies. Imaging studies. Proton density fat-saturated MRI sequence demonstrates an increased signal within the semimembranosus and biceps femoris.

Imaging studies. Imaging studies. Proton density fat-saturated MRI sequence demonstrates an increased signal within the semimembranosus and biceps femoris.
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Relationship between self-reported adherence to USPSTF/ADA guidelines and evidence from EMR.† The concordance analysis was performed on only 281 surveyed.

Relationship between self-reported adherence to USPSTF/ADA guidelines and evidence from EMR.† The concordance analysis was performed on only 281 surveyed.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.
Obesity and type 2 diabetes forecasts.

Obesity and type 2 diabetes forecasts.
(A–B) Box plot representing the median relative expression of CD300LG mRNA in skeletal muscle (A) and in SAT (B) by CD300LG genotype. (A–B) Box plot representing.

(A–B) Box plot representing the median relative expression of CD300LG mRNA in skeletal muscle (A) and in SAT (B) by CD300LG genotype. (A–B) Box plot representing.
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.

Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

Similar presentations

Ads by Google